The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 351:354-361 July 22, 2004 Number 4
NextNext

Methylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis
Michael Strupp, M.D., Vera Carina Zingler, M.D., Viktor Arbusow, M.D., Daniel Niklas, Klaus Peter Maag, M.D., Ph.D., Marianne Dieterich, M.D., Sandra Bense, M.D., Diethilde Theil, D.V.M., Klaus Jahn, M.D., and Thomas Brandt, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Perspective
 by Johnson, R. T.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background Vestibular neuritis is the second most common cause of peripheral vestibular vertigo. Its assumed cause is a reactivation of herpes simplex virus type 1 infection. Therefore, corticosteroids, antiviral agents, or a combination of the two might improve the outcome in patients with vestibular neuritis.

Methods We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir. Vestibular function was determined by caloric irrigation, with the use of the vestibular paresis formula (to measure the extent of unilateral caloric paresis) within 3 days after the onset of symptoms and 12 months afterward.

Results Of a total of 141 patients who underwent randomization, 38 received placebo, 35 methylprednisolone, 33 valacyclovir, and 35 methylprednisolone plus valacyclovir. At the onset of symptoms there was no difference among the groups in the severity of vestibular paresis. The mean (±SD) improvement in peripheral vestibular function at the 12-month follow-up was 39.6±28.1 percentage points in the placebo group, 62.4±16.9 percentage points in the methylprednisolone group, 36.0±26.7 percentage points in the valacyclovir group, and 59.2±24.1 percentage points in the methylprednisolone-plus-valacyclovir group. Analysis of variance showed a significant effect of methylprednisolone (P<0.001) but not of valacyclovir (P=0.43). The combination of methylprednisolone and valacyclovir was not superior to corticosteroid monotherapy.

Conclusions Methylprednisolone significantly improves the recovery of peripheral vestibular function in patients with vestibular neuritis, whereas valacyclovir does not.


Source Information

From the Departments of Neurology (M.S., V.C.Z., V.A., D.N., D.T., K.J., T.B.) and Epidemiology and Biometrics (K.P.M.), University of Munich, Munich; and the Department of Neurology, University of Mainz, Mainz (M.D., S.B.) — both in Germany.

Address reprint requests to Dr. Strupp at the Department of Neurology, University of Munich, Klinikum Grosshadern, Marchioninistr. 15, 81377 Munich, Germany, or at mstrupp{at}nefo.med.uni-muenchen.de.

Full Text of this Article


Related Letters:

Methylprednisolone, Valacyclovir, or Both for Vestibular Neuritis
Sood A., Ebbert J. O., Vroomen P., Tenser R. B., Strupp M., Theil D., Brandt T.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2344-2345, Nov 25, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.